For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
Voyager Therapeutics Inc (NASDAQ: VYGR) closed the day trading at $3.65 up 7.67% from the previous closing price of $3.39. In other words, the price has increased by $7.67 from its previous closing price. On the day, 1.23 million shares were traded. VYGR stock price reached its highest trading level at $3.77 during the session, while it also had its lowest trading level at $3.41.
Ratios:
For a better understanding of VYGR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.43 and its Current Ratio is at 5.43. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.13.
On December 02, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $12.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 02 ’25 when Ferguson Toby sold 10,086 shares for $3.43 per share. The transaction valued at 34,595 led to the insider holds 157,914 shares of the business.
Sandrock Alfred sold 10,885 shares of VYGR for $37,336 on Apr 02 ’25. The President and CEO now owns 430,931 shares after completing the transaction at $3.43 per share. On Apr 02 ’25, another insider, Sandrock Alfred, who serves as the Officer of the company, bought 10,885 shares for $3.43 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VYGR now has a Market Capitalization of 202461120 and an Enterprise Value of 27072142. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.75 while its Price-to-Book (P/B) ratio in mrq is 0.83. Its current Enterprise Value per Revenue stands at 0.636 whereas that against EBITDA is -0.228.
Stock Price History:
The Beta on a monthly basis for VYGR is 0.90, which has changed by -0.43759632 over the last 52 weeks, in comparison to a change of 0.16657472 over the same period for the S&P500. Over the past 52 weeks, VYGR has reached a high of $8.27, while it has fallen to a 52-week low of $2.64. The 50-Day Moving Average of the stock is 12.60%, while the 200-Day Moving Average is calculated to be -16.68%.
Shares Statistics:
Over the past 3-months, VYGR traded about 744.78K shares per day on average, while over the past 10 days, VYGR traded about 1074300 shares per day. A total of 55.43M shares are outstanding, with a floating share count of 45.29M. Insiders hold about 18.34% of the company’s shares, while institutions hold 62.98% stake in the company. Shares short for VYGR as of 1753920000 were 3214674 with a Short Ratio of 4.32, compared to 1751241600 on 4443195. Therefore, it implies a Short% of Shares Outstanding of 3214674 and a Short% of Float of 6.92.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
A comprehensive evaluation of Voyager Therapeutics Inc (VYGR) is underway, with the input of 10.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.48, with high estimates of -$0.34 and low estimates of -$0.61.
Analysts are recommending an EPS of between -$1.77 and -$2.3 for the fiscal current year, implying an average EPS of -$2.11. EPS for the following year is -$1.41, with 10.0 analysts recommending between -$0.48 and -$2.64.
Revenue Estimates
12 analysts predict $7.86M in revenue for the current quarter. It ranges from a high estimate of $12.5M to a low estimate of $5M. As of the current estimate, Voyager Therapeutics Inc’s year-ago sales were $24.63MFor the next quarter, 12 analysts are estimating revenue of $10.54M. There is a high estimate of $23.4M for the next quarter, whereas the lowest estimate is $5M.
A total of 12 analysts have provided revenue estimates for VYGR’s current fiscal year. The highest revenue estimate was $45.13M, while the lowest revenue estimate was $21.67M, resulting in an average revenue estimate of $30.08M. In the same quarter a year ago, actual revenue was $80MBased on 12 analysts’ estimates, the company’s revenue will be $62.28M in the next fiscal year. The high estimate is $145.95M and the low estimate is $8M.
